360Dx

Paradigm Diagnostics Raises Additional $3M in Series B Round

Feb 16, 2017

NEW YORK (GenomeWeb) – Paradigm Diagnostics announced today that it has secured an additional $3 million in funding as part of a planned $7 million Series B round of financing.

The investment was made by New Science Ventures and follows a $3.5 million investment led by Mesa Verde Venture Partners in November. New Science Ventures Partner Grace Colón also joined Paradigm's board.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Paradigm Diagnostics Raises Additional $3M in Series B Round

To read the full story....

Breaking News

BioReference Settles False Claims, Kickback Allegations for $11.5M

Quest, Walmart Teaming Up to Deliver SARS-CoV-2 Home Sampling Kits Via Drone

UBS Downgrades Illumina to Neutral; Expresses Doubts About Grail Deal

FDA Grants Emergency Use Authorization for GK Pharmaceuticals Coronavirus Test

Promega to Develop MSI Assay as CDx for Incyte Endometrial Cancer Drug

Genosity Inks Comarketing Agreement with Personal Genome Diagnostics

Featured White Papers

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

What's Popular?

Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider

JP Morgan Downgrades Illumina to Neutral on Grail Deal

Illumina to Acquire Grail for $8B in Cash and Stock

UBS Downgrades Illumina to Neutral; Expresses Doubts About Grail Deal

Genosity Inks Comarketing Agreement with Personal Genome Diagnostics

Sponsorships